Decentralized Clinical Trials — Is There a Positive Return on Investment on a Virtual Site?
Across the Life Sciences industry, there has been much talk about the cost and value of decentralized clinical trials (DCT) and the potential return on investment (ROI) when the expedited time to commercialization is considered. When faced with an 80% delay rate due to a myriad of reasons, the industry is potentially facing more than 51,000 delayed trials globally— not including new trials beginning in upcoming months and years.
With most studies likely including a combination of traditional and virtual sites, Science 37 has examined the cost and value impact of differing numbers of brick-and-mortar sites deployed in combination with a virtual site.
Download our newest white paper and learn more about:
- Key drivers of decentralized clinical trial value
- Scenarios that show the value delivered with a mix of traditional and virtual sites
- And how to optimize trial design to meet key objectives such as time, cost, risk mitigation, and more.